Refine your search
Collections
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Zhong, Bo
- Anti-Tumour and Immune Enhancing Activities of MLAA-22379–387 on Acute Myeloid Leukemia
Abstract Views :265 |
PDF Views:80
Authors
Jing Li
1,
Wanggang Zhang
2,
Ju Bai
2,
Bo Zhong
1,
Huiyuan Wang
1,
Yan Geng
1,
Qiaoyan Jin
1,
Juanjuan Hao
1,
Yang Zhang
1
Affiliations
1 Department of Pediatrics, Medical School of Xi’an Jiaotong University, Xi’an Xincheng Xiwu Road 157, Xi’an 710004, Shaanxi Province, CN
2 Department of Hematology, Medical School of Xi’an Jiaotong University, Xi’an Xincheng Xiwu Road 157, Xi’an 710004, Shaanxi Province, CN
1 Department of Pediatrics, Medical School of Xi’an Jiaotong University, Xi’an Xincheng Xiwu Road 157, Xi’an 710004, Shaanxi Province, CN
2 Department of Hematology, Medical School of Xi’an Jiaotong University, Xi’an Xincheng Xiwu Road 157, Xi’an 710004, Shaanxi Province, CN
Source
Current Science, Vol 118, No 6 (2020), Pagination: 892-900Abstract
We have earlier demonstrated that MLAA-22379–387is a novel, acute, monocytic, leukemia-associated antigen epitope in vitro. In this study, the effect and mechanism of MLAA-22379–387on animals have been further examined. We found that tumour weight and volume had significantly decreased in SCID-injected THP-1 mice with MLAA-22379–387treatment for two weeks. MLAA-22379–387induced cytotoxic T lymphocytes (CTL) activity in A549, MCF-7, THP-1, U937 and T2 cells, especially significant CTL activity at effector/target ratio of 50 : 1 in THP-1 cells. The percentage of CD3 + CD8 + T cells had significantly increased, while the percentage of CD4 + CD25 + T cells had significantly decreased in MLAA-22379–387treatment group compared to other groups. Levels of IL-2, IFN-γand IgG had significantly increased, but levels of TGF-βand IL-10 had significantly decreased after MLAA-22379–387vac-cination for two weeks. Thus, we may conclude that MLAA-22379–387treatment effectively improves the immune system, thus indicating tumouricidal capacity in leukaemic mice. These findings highlight the potential application of MLAA-22379–387 as an efficient target for immunotherapy in acute myeloid leukemia.Keywords
Acute Myeloid Leukemia, Anti-Tumour Activity, Immunotherapy, Mice.Full Text
References
- Deschler, B. and Lubbert, M., Acute myeloid leukemia: epidemiology and etiology. Cancer, 2006, 107, 2099–2107.
- Schlenk, R. F. and Döhner, H., Genomic applications in the clinic: use in treatment paradigm of acute myeloid leukemia. Hematol. Am. Soc. Hematol. Educ. Program., 2013, 1, 324–330.
- Appelbaum, F. R. et al., Age and acute myeloid leukemia. Blood, 2006, 107, 481–485.
- Khalil, D. N., Smith, E. L., Brentjens, R. J. and Wolchok, J. D., The future of cancer treatment: immunomodulation, CARs and combination immunotherapy. Nature Rev. Clin. Oncol., 2016, 13, 273–290.
- Acheampong, D. O. et al., Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy. Biomed. Pharmacother., 2018, 97, 225–232.
- Grosso, D. A., Hess, R. C. and Weiss, M. A., Immunotherapy in acute myeloid leukemia. Cancer, 2015, 121, 2689–2704.
- Kolb, H. J., Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood, 2008, 112, 4371–4383.
- Walter, R. B. et al., Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood, 2012, 119, 6198–6208.
- Schurch, C. M., Riether, C. and Ochsenbein, A. F., Dendritic cell-based immunotherapy for myeloid leukemias. Front. Immunol., 2013, 4, 496.
- Kobayashi, Y. et al., A new peptide vaccine OCV-501: in vitropharmacology and phase 1 study in patients with acutemyeloid leukemia. Cancer Immunol. Immunother., 2017, 66, 851– 863.
- Molldrem, J. et al., Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood, 1996, 88, 2450–2457.
- Greiner, J. et al., Characterization of several leukemia-associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia. Int. J. Cancer, 2013, 106, 224–231.
- Sohn, H. J. et al., Simultaneous in vitrogeneration of CD8 and CD4 T cells specific to three universal tumour associated antigens of WT1, survivin and TERT and adoptive T cell transfer for the treatment of acute myeloid leukemia. Oncotarget, 2017, 8, 44059– 44072.
- Zhou, F. L. et al., Bioinformatic analysis and identification for a novel antigen MLAA-22 in acutemonocytic leukemia. J. Exp. He-matol. Chin. Assoc. Pathophysiol., 2008, 16, 466–471.
- Gu, L. F. et al., Expression and clinical significance of MLAA-22 in acute monocytic leukemia. Mod. Oncol., 2018, 26, 2753–2756.
- Li, J. et al., Prediction and identification of HLA-A*0201-restricted epitopes from leukemia-associated protein MLAA-22 which elicit cytotoxic T lymphocytes. Med. Oncol., 2014, 31, 293.
- Sharma, A. et al., Safety and blood sample volume and quality of a refined retro-orbital bleeding technique in rats using a lateral approach. Lab. Anim. (NY), 2014, 43, 63–66.
- Przespolewski, A., Szeles, A. and Wang, E. S., Advances in immunotherapy for acute myeloid leukemia. Future Oncol., 2018, 14, 963–978.
- Zhou, Q. et al., Humanized NOD-SCID IL2rg–/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies. Cancer Lett., 2014, 1, 13–19.
- Amrita, D. and Debasis, M., Chapter 5 – development of mouse models for cancer research. Anim. Biotechnol., 2014, 73–94.
- Edward, R. et al., Advances in patient-derived tumor xenografts: from target identification to predicting clinical response rates in oncology. Biochem. Pharmacol., 2014, 2, 135–143.
- Chua, B. Y. et al., Dendritic cell acquisition of epitope cargo mediated by simple cationic peptide structures. Peptides, 2008, 29, 881–890.
- Guo, Z. et al., DCs pulsed with novel HLA-A2-restricted CTL epitopes against hepatitis C virus induced a broadly reactive anti-HCV-specific T lymphocyte response. PLoS ONE, 2012, 7, e38390.
- Lasa, A. et al., WT1 monitoring in core binding factor AML: Comparison with specific chimeric products. Leuk. Res., 2009, 12, 1643–1649.
- Kim, M. Y. et al., Function of CD4+ CD3– cells in relation to B- and T-zone stroma in spleen. Blood, 2007, 109, 1602–1610.
- McKinney, D. E. F. et al., Signatures of CD4 T-cell help and CD8 exhaustion predict clinical outcome in autoimmunity, infection, and vaccination. Lancet, 2013, 381, 74.
- Sakaguchi, S., Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nature Immunol., 2005, 6, 345–352.
- Son, C. H. et al., Enhancement of antitumor immunity by combination of anti-CTLA-4 antibody and radioimmunotherapy through the suppression of Tregs. Oncol. Lett., 2017, 13, 3781–3786.
- Liu, J. F. et al., Blockade of TIM3 relieves immunosuppression through reducing regulatory T cells in head and neck cancer. J. Exp. Clin. Cancer Res., 2018, 37, 44.
- Yang, Z. Z. et al., Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma.Blood, 2006, 107, 3639–3646.
- Hope, C. M. et al., The immune phenotype may relate to cancer development in kidney transplant recipients. Kidney Int., 2014, 86, 175–183.
- Boyman, O. and Sprent, J., The role of interleukin-2 during homeostasis and activation of the immune system. Nature Rev. Immunol., 2012, 12, 180–190.
- Loria-Cervera, E. N., Cloning and sequence analysis of Peromys-cus yucatanicus(Rodentia) Th1 (IL-12p35, IFN-γand TNF) and Th2 (IL-4, IL-10 and TGF-β) cytokines. Cytokine, 2014, 65, 48– 55.
- Dunn, G. P., Koebel, C. M. and Schreiber, R. D., Interferons, immunity and cancer immunoediting. Nature Rev. Immunol., 2006, 6, 836–848.
- Qiu, X. et al., Immunoglobulin gamma heavy chain gene with somatic hypermutation is frequently expressed in acute myeloid leukemia. Leukemia, 2013, 27, 92–99.
- Mocellin, S., Marincola, F. M. and Young, H. A., Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukocyte Biol., 2005, 78, 1043–1051.
- Massague, J., TGF beta signalling in context. Nature Rev. Mol. Cell Biol., 2012, 13, 616–630.
- Massague, J. and Obenauf, A. C., Metastatic colonization by circulating tumour cells. Nature, 2016, 529, 298–306.
- Kim, J. Y. et al., Inhibition of dextran sulfate sodium (DSS)-induced intestinal inflammation via enhanced IL-10 and TGF-β production by galectin-9 homologues isolated from intestinal parasites. Mol. Biochem. Parasitol., 2010, 174, 53–61.